Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

Beta Bionics Explodes to $65.1M in Revenue - Orange County Business Journal

One of Orange County’s fastest-growing public companies only went public two months ago. Beta Bionics Inc.’s concept of an artificial pancreas that regulates blood sugar levels in people with type 1 diabetes (T1D) was well received by Wall Street. It raised an upsized $234.6 million during its January debut, $120 million more than planned. On its first day, shares rose as much as 44% to $24.50 and a $1 billion valuation (Nasdaq: BBNX). The Irvin…

Type 1 Diabetes: Understanding Disease Progression and Beta Cell Function

A panelist discusses how type 1 diabetes (T1D) is a complex autoimmune disease characterized by progressive beta cell destruction that advances through distinct stages, with genetic predisposition, environmental triggers and the presence of specific autoantibodies serving as key risk factors and diagnostic markers.

New clinical practice guidelines for type 1 diabetes released

On March 27, 2025 Diabetes Canada released updated Clinical Practice Guidelines for the glycemic management across the lifespan for people with type 1 diabetes. What are clinical practice guidelines and what do they mean for people with type 1 diabetes (T1D)? Clinical guidelines are the guiding principles for health care practitioners to stay up to date on best practices in the management and care of people living with all diseases, including ty…